Payment overview · 2025
General Payments
$907.83
47 reported records · 17 companies
Healthcare provider profile · identity verified
Vel Natesan, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SALISBURY, MD · NPI 1457372310
Verified facts
What the public records show
CMS Open Payments records show Vel Natesan, M.D. received $907.83 in general payments during 2025 across 47 reported records.
Amgen Inc. accounted for 23.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Gemtesa, Jardiance, Mounjaro, Ozempic, Trintellix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 162 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 202 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 406 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 494 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 406 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 344 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 494 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Gemtesa by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $211.11 | 23.2% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $140.19 | 15.4% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $108.84 | 12.0% | 6 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $77.50 | 8.5% | 5 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $48.15 | 5.3% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $47.18 | 5.2% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $37.84 | 4.2% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $37.76 | 4.2% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $37.30 | 4.1% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $34.51 | 3.8% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $27.33 | 3.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.57 | 2.4% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $16.47 | 1.8% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $16.38 | 1.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.81 | 1.7% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $15.08 | 1.7% | 1 | 2025 |
| Soleno Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.81 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $907.83 | 47 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $172.15 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $105.53 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $105.53 | 5 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $77.50 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $58.60 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $51.31 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $50.24 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $50.24 | 3 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $48.15 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $37.76 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $37.30 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $34.66 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $34.51 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $32.98 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $28.62 | 1 | 2025 |
Source payment records
|
|||||
| AMS 700 Normalized: ams 700 |
Device | Boston Scientific Corporation | $27.33 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $24.30 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $24.30 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $21.57 | 1 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $18.30 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $16.47 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $16.38 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.81 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.81 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $15.08 | 1 | 2025 |
Source payment records
|
|||||
| VYKAT XR Normalized: vykat xr |
Drug | Soleno Therapeutics, Inc. | $14.81 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $13.54 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $13.54 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $10.34 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 494 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 58 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 406 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 133 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 344 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
32 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
162 | 43 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
202 | 43 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
406 | 97 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
494 | 107 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
406 | 97 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
133 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
77 | 23 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
56 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
344 | 78 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
494 | 107 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
42 | 42 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
58 | 19 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1527 | 445 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1297 | 337 |
| Amlodipine Besylate | Amlodipine Besylate | 1132 | 308 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1025 | 277 |
| Pantoprazole Sodium | Pantoprazole Sodium | 686 | 197 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 673 | 180 |
| Metoprolol Succinate | Metoprolol Succinate | 553 | 142 |
| Tamsulosin Hcl | Tamsulosin Hcl | 536 | 142 |
| Eliquis | Apixaban | 494 | 107 |
| Potassium Chloride | Potassium Chloride | 484 | 138 |
| Gabapentin | Gabapentin | 448 | 126 |
| Losartan Potassium | Losartan Potassium | 419 | 113 |
| Jardiance | Empagliflozin | 406 | 97 |
| Furosemide | Furosemide | 390 | 116 |
| Fluticasone Propionate | Fluticasone Propionate | 379 | 171 |
| Metformin Hcl | Metformin Hcl | 368 | 103 |
| Irbesartan | Irbesartan | 363 | 104 |
| Lisinopril | Lisinopril | 352 | 102 |
| Ozempic | Semaglutide | 344 | 78 |
| Escitalopram Oxalate | Escitalopram Oxalate | 341 | 88 |
| Metformin Hcl Er | Metformin Hcl | 324 | 80 |
| Glipizide Er | Glipizide | 323 | 77 |
| Ezetimibe | Ezetimibe | 309 | 91 |
| Sertraline Hcl | Sertraline Hcl | 286 | 85 |
| Alprazolam | Alprazolam | 284 | 61 |
| Omeprazole | Omeprazole | 255 | 67 |
| Famotidine | Famotidine | 252 | 78 |
| Allopurinol | Allopurinol | 240 | 62 |
| Tramadol Hcl | Tramadol Hcl | 237 | 56 |
| Montelukast Sodium | Montelukast Sodium | 235 | 71 |
| Pravastatin Sodium | Pravastatin Sodium | 229 | 64 |
| Valsartan | Valsartan | 221 | 65 |
| Metoprolol Tartrate | Metoprolol Tartrate | 217 | 69 |
| Simvastatin | Simvastatin | 214 | 68 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 210 | 46 |
| Trazodone Hcl | Trazodone Hcl | 206 | 63 |
| Farxiga | Dapagliflozin Propanediol | 202 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 200 | 67 |
| Carvedilol | Carvedilol | 195 | 53 |
| Zolpidem Tartrate | Zolpidem Tartrate | 193 | 46 |
| Duloxetine Hcl | Duloxetine Hcl | 183 | 49 |
| Spironolactone | Spironolactone | 177 | 53 |
| Clonazepam | Clonazepam | 175 | 37 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 175 | 55 |
| Clonidine Hcl | Clonidine Hcl | 172 | 43 |
| Xarelto | Rivaroxaban | 167 | 38 |
| Labetalol Hcl | Labetalol Hcl | 163 | 44 |
| Synthroid | Levothyroxine Sodium | 162 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 158 | 74 |
| Hydralazine Hcl | Hydralazine Hcl | 154 | 39 |
| Donepezil Hcl | Donepezil Hcl | 152 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 136 | 37 |
| Mounjaro | Tirzepatide | 133 | 30 |
| Lorazepam | Lorazepam | 130 | 47 |
| Prednisone | Prednisone | 124 | 70 |
| Atenolol | Atenolol | 118 | 31 |
| Fenofibrate | Fenofibrate | 113 | 29 |
| Finasteride | Finasteride | 113 | 33 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 111 | 33 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 107 | 32 |
| Torsemide | Torsemide | 105 | 32 |
| Fenofibrate | Fenofibrate Nanocrystallized | 102 | 31 |
| Bupropion Xl | Bupropion Hcl | 101 | 24 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 100 | 25 |
| Doxycycline Hyclate | Doxycycline Hyclate | 99 | 92 |
| Nifedipine Er | Nifedipine | 99 | 31 |
| Nebivolol Hcl | Nebivolol Hcl | 98 | 28 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 98 | 80 |
| Azithromycin | Azithromycin | 95 | 79 |
| Januvia | Sitagliptin Phosphate | 91 | 20 |
| Mirtazapine | Mirtazapine | 90 | 27 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 90 | 13 |
| Meloxicam | Meloxicam | 89 | 39 |
| Amiodarone Hcl | Amiodarone Hcl | 86 | 24 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 86 | 23 |
| Clonidine | Clonidine | 83 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 83 | 18 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 82 | 25 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 81 | 23 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 80 | 19 |
| Buspirone Hcl | Buspirone Hcl | 78 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 78 | 50 |
| Trulicity | Dulaglutide | 77 | 23 |
| Celecoxib | Celecoxib | 76 | 28 |
| Glimepiride | Glimepiride | 76 | 21 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 75 | 12 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 75 | 24 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 74 | 53 |
| Enalapril Maleate | Enalapril Maleate | 71 | 17 |
| Breo Ellipta | Fluticasone/Vilanterol | 70 | 14 |
| Eszopiclone | Eszopiclone | 66 | 16 |
| Digoxin | Digoxin | 59 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 59 | 26 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 59 | 42 |
| Gemtesa | Vibegron | 58 | 19 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 57 | 18 |
| Colchicine | Colchicine | 56 | 19 |
| Entresto | Sacubitril/Valsartan | 56 | 15 |
| Myrbetriq | Mirabegron | 56 | 11 |
| Memantine Hcl | Memantine Hcl | 55 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 55 | 14 |
| Midodrine Hcl | Midodrine Hcl | 54 | 17 |
| Pregabalin | Pregabalin | 54 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 53 | 42 |
| Fluoxetine Hcl | Fluoxetine Hcl | 53 | 18 |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 52 | 15 |
| Sucralfate | Sucralfate | 52 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 51 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 51 | 15 |
| Alendronate Sodium | Alendronate Sodium | 50 | 14 |
| Fluconazole | Fluconazole | 50 | 36 |
| Ibuprofen | Ibuprofen | 49 | 18 |
| Ipratropium Bromide | Ipratropium Bromide | 49 | 21 |
| Propranolol Hcl Er | Propranolol Hcl | 49 | suppressed |
| Methylprednisolone | Methylprednisolone | 48 | 44 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 47 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 47 | 16 |
| Nitroglycerin | Nitroglycerin | 47 | 35 |
| Sumatriptan Succinate | Sumatriptan Succinate | 47 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 45 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 45 | 17 |
| Glipizide | Glipizide | 45 | 13 |
| Ondansetron Odt | Ondansetron | 45 | 29 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 45 | 33 |
| Temazepam | Temazepam | 45 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 44 | 11 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 44 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 43 | 42 |
| Azelastine Hcl | Azelastine Hcl | 43 | 17 |
| Levetiracetam | Levetiracetam | 43 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 43 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 42 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 42 | 42 |
| Valacyclovir | Valacyclovir Hcl | 39 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 38 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 38 | 12 |
| Nortriptyline Hcl | Nortriptyline Hcl | 37 | suppressed |
| Nystatin | Nystatin | 34 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 34 | suppressed |
| Cephalexin | Cephalexin | 33 | 28 |
| Dutasteride | Dutasteride | 33 | suppressed |
| Tradjenta | Linagliptin | 33 | suppressed |
| Baclofen | Baclofen | 32 | suppressed |
| Linzess | Linaclotide | 32 | 13 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 32 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | suppressed |
| Ramipril | Ramipril | 31 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 30 | suppressed |
| Lactulose | Lactulose | 30 | suppressed |
| Lansoprazole | Lansoprazole | 30 | suppressed |
| Latanoprost | Latanoprost | 30 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 30 | suppressed |
| Primidone | Primidone | 30 | suppressed |
| Eplerenone | Eplerenone | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | 12 |
| Lovastatin | Lovastatin | 29 | suppressed |
| Repatha Sureclick | Evolocumab | 29 | suppressed |
| Rivastigmine | Rivastigmine | 29 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 29 | 11 |
| Amoxicillin | Amoxicillin | 28 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 27 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 27 | suppressed |
| Estradiol | Estradiol | 27 | 13 |
| Metoclopramide Hcl | Metoclopramide Hcl | 27 | suppressed |
| Novolog Flexpen | Insulin Aspart | 26 | suppressed |
| Cartia Xt | Diltiazem Hcl | 25 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 25 | suppressed |
| Ketoconazole | Ketoconazole | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 24 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 24 | suppressed |
| Lidocaine | Lidocaine | 23 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 23 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 22 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 19 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 21 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 21 | 14 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 21 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 21 | suppressed |
| Niacin Er | Niacin | 21 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Sulfasalazine | Sulfasalazine | 19 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 18 | suppressed |
| Pentoxifylline | Pentoxifylline | 18 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 17 | suppressed |
| Creon | Lipase/Protease/Amylase | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 17 | suppressed |
| Acetazolamide | Acetazolamide | 16 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 16 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 16 | 13 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 16 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 16 | suppressed |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Movantik | Naloxegol Oxalate | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 15 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 14 |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 14 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 14 | suppressed |
| Carisoprodol | Carisoprodol | 14 | suppressed |
| Constulose | Lactulose | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Erythromycin | Erythromycin Base | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Nystop | Nystatin | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 12 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 12 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 11 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 11 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Nadolol | Nadolol | 11 | suppressed |
| Nexium | Esomeprazole Magnesium | 11 | suppressed |
| Phenytoin | Phenytoin | 11 | suppressed |
| Sulfasalazine Dr | Sulfasalazine | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
| Verapamil Sr | Verapamil Hcl | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $907.83 · 47 records | Amgen Inc. | ABRYSVO, AIRSUPRA, AMS 700, AMYVID, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FUROSCIX, GEMTESA, JARDIANCE, KISUNLA, KRYSTEXXA, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, TRINTELLIX, UBRELVY, VYKAT XR, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND, ZORYVE | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error